These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24585270)

  • 21. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
    Rawal T; Parmar R; Tyagi RK; Butani S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
    Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on the use of rifapentine for tuberculosis therapy.
    Chan JG; Bai X; Traini D
    Expert Opin Drug Deliv; 2014 Mar; 11(3):421-31. PubMed ID: 24397259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach.
    Patil-Gadhe A; Pokharkar V
    Pulm Pharmacol Ther; 2014 Apr; 27(2):197-207. PubMed ID: 23916767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution.
    Singh C; Koduri LV; Dhawale V; Bhatt TD; Kumar R; Grover V; Tikoo K; Suresh S
    Int J Pharm; 2015 Nov; 495(2):627-32. PubMed ID: 26392246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
    Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhalable dry powders of rifampicin highlighting potential and drawbacks in formulation development for experimental tuberculosis aerosol therapy.
    Berkenfeld K; McConville JT; Lamprecht A
    Expert Opin Drug Deliv; 2020 Mar; 17(3):305-322. PubMed ID: 32017637
    [No Abstract]   [Full Text] [Related]  

  • 29. Capreomycin inhalable powders prepared with an innovative spray-drying technique.
    Schoubben A; Giovagnoli S; Tiralti MC; Blasi P; Ricci M
    Int J Pharm; 2014 Jul; 469(1):132-9. PubMed ID: 24747443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats.
    Khadka P; Sinha S; Tucker IG; Dummer J; Hill PC; Katare R; Das SC
    Eur J Pharm Biopharm; 2021 May; 162():1-11. PubMed ID: 33639255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
    Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
    Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
    Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin.
    Manca ML; Valenti D; Sales OD; Nacher A; Fadda AM; Manconi M
    Int J Pharm; 2014 Sep; 472(1-2):102-9. PubMed ID: 24928129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
    Dorman SE; Goldberg S; Stout JE; Muzanyi G; Johnson JL; Weiner M; Bozeman L; Heilig CM; Feng PJ; Moro R; Narita M; Nahid P; Ray S; Bates E; Haile B; Nuermberger EL; Vernon A; Schluger NW;
    J Infect Dis; 2012 Oct; 206(7):1030-40. PubMed ID: 22850121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.
    Pitner RA; Durham PG; Stewart IE; Reed SG; Cassell GH; Hickey AJ; Carter D
    J Pharm Sci; 2019 Oct; 108(10):3302-3311. PubMed ID: 31152746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
    Daniel N; Lounis N; Ji B; O'Brien RJ; Vernon A; Geiter LJ; Szpytma M; Truffot-Pernot C; Hejblum G; Grosset J
    Am J Respir Crit Care Med; 2000 May; 161(5):1572-7. PubMed ID: 10806157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products.
    Müller T; Krehl R; Schiewe J; Weiler C; Steckel H
    Eur J Pharm Biopharm; 2015 May; 92():130-8. PubMed ID: 25769680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance.
    Patil-Gadhe A; Kyadarkunte A; Patole M; Pokharkar V
    Eur J Pharm Biopharm; 2014 Sep; 88(1):169-77. PubMed ID: 25078860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
    Ohashi K; Kabasawa T; Ozeki T; Okada H
    J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.